Valuation: Monopar Therapeutics Inc.

Market Cap 744M 651M 600M 553M 1.04B 71.68B 1.07B 7.17B 2.82B 35.11B 2.8B 2.73B 121B P/E 2026 *
-48.2x
P/E 2027 * -32.1x
Enterprise Value 626M 547M 505M 465M 877M 60.27B 896M 6.03B 2.37B 29.52B 2.35B 2.3B 102B EV / Sales 2026 *
-
EV / Sales 2027 * 39.9x
Free-Float
76.58%
Yield 2026 *
-
Yield 2027 * -
1 day+2.40%
1 week+4.24%
Current month+20.01%
1 month+64.70%
3 months+97.65%
6 months+58.74%
Current year+70.17%
1 week 97.93
Extreme 97.93
111.94
1 month 66.82
Extreme 66.825
112.57
Current year 50.07
Extreme 50.07
112.57
1 year 29.18
Extreme 29.18
112.57
3 years 1.37
Extreme 1.3695
112.57
5 years 1.37
Extreme 1.3695
112.57
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2014
Director of Finance/CFO 54 02/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 28/02/2023
Chairman 73 30/11/2014
Director/Board Member 84 31/03/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
+2.40%+4.24%+139.07%+2,597.09% 744M
+0.02%-3.33%+1.32%+3.01% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.47% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+0.51%+1.67%+14.75%+17.53% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +0.36%+0.45%+74.31%+375.48% 24.44B
Weighted average by Cap. +0.19%-0.17%+80.01%+130.59%

Financials

2026 *2027 *
Net sales - 15.85M 13.85M 12.78M 11.78M 22.21M 1.53B 22.7M 153M 60.09M 748M 59.52M 58.22M 2.57B
Net income -20.16M -17.62M -16.26M -14.99M -28.25M -1.94B -28.87M -194M -76.43M -951M -75.71M -74.05M -3.27B -35.78M -31.27M -28.85M -26.59M -50.12M -3.45B -51.24M -345M -136M -1.69B -134M -131M -5.81B
Net Debt -119M -104M -95.61M -88.13M -166M -11.42B -170M -1.14B -449M -5.59B -445M -436M -19.25B -112M -98.17M -90.59M -83.5M -157M -10.82B -161M -1.08B -426M -5.3B -422M -413M -18.24B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
17/07/26 US$111.12 +2.40% 265,227
16/07/26 US$108.52 -0.16% 193,675
15/07/26 US$108.69 +8.92% 177,109
14/07/26 US$99.79 -3.43% 498,249
13/07/26 US$103.33 -3.07% 214,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
111.12USD
Average target price
113.62USD
Spread / Average Target
+2.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock